Home About Us Product Pipeline News Releases Careers Contact
UMN Pharma is a specialty pharmaceutical company focused on developing new and innovative products. We license highly-selected therapeutic candidates from leading academic institutions and public research organizations, develop them to value-added inflection points, and then partner them for further development and/or sales and marketing with larger partners in the pharmaceutical industry.
Unmet Medical Needs   UMN Pharma Inc. is a pharmaceutical company that develops innovative product candidates to meet unmet medical needs.  
News Releases
  June 18, 2008

UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

  June 10, 2008

UMN's pandemic influenza vaccine, UMN-0501 designated as orphan drug.

  May 19, 2008

UMN Pharma presents at DIGESTIVE DESEASE WEEK 2008 in San Diego, California.

  April 30, 2008

UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.

  April 10, 2008

UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN’s pandemic influenza vaccine.

  April 2008

UMN Pharma appoints Mr. Masahiro Hayashi as a new Director of the company.

  November 2007

UMN Pharma appoints Dr. Shuichi Kanazashi as its new President and CEO.

Corporate Vision
The goals of UMN Pharma Inc. are to ·       Fully exercise the drug development skills that we acquired during previous years spent in the international pharmaceutical industry ·       Develop products with know-how, speed and efficiency ·       Provide medications that fill major therapeutic needs and save lives.